Acal (LON:ACL) - A HyACT to follow

Monday, Mar 25 2013 by

Mar 25th 2013 - Edison Investment Research today published a report on Acal (ACL.L, LSE:ACL, LON:ACL) entitled "A HyACT To Follow". In summary, the report says:

Alchemia’s c 60% share price decline after the failed spin-out of its oncology division, Audeo, belies a promising late stage cancer candidate incorporating the company’s HyACT drug delivery platform. A Phase III trial of Audeo’s lead product HA-Irinotecan versus conventional irinotecan as part of the FOLFIRI regime in second/third line metastatic colorectal cancer is fully recruited and should read out results in early 2014. Favourable data may pave the way for US approval in 2015 and validate the HyACT platform (in which drugs are co-formulated with hyaluronic acid) for use with other chemotherapeutic agents.




About Edison Investment Research

Edison Investment Research

Follow

Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »


 
Join us at the London Investor Show next Friday at Olympia